Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(p henylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide

Details for Australian Patent Application No. 2005272074 (hide)

International Classifications

Event Publications

11 January 2007 PCT application entered the National Phase

PCT publication WO2006/016995 Priority application(s): WO2006/016995

19 April 2007 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 13 Feb 2007

1 November 2007 Change of Name(s) of Applicant(s), Section 104

Sapphire Therapeutics, Inc. The name of the applicant has been changed to Albany Molecular Research, Inc.; Sapphire Therapeutics, Inc.

22 November 2007 Amendment Made

The nature of the amendment is: Add co-inventors Littler, Benjamin and Paul, Bernhard

11 June 2009 Assignment before Grant

Sapphire Therapeutics, Inc.; Albany Molecular Research, Inc. The application has been assigned to Albany Molecular Research, Inc.; Helsinn Therapeutics (U.S.), Inc.

24 November 2011 Application Accepted

Published as AU-B-2005272074

22 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.